CD163 and the FVIII/FXII ratio identified as novel biomarkers for early sepsis recognition

Back to news list

Source: Frontiers Medicine

Original: https://www.frontiersin.org/articles/10.3389/fmed.2026.1682209...

Published: 2026-02-04T00:00:00Z

The study analyzed 1,245 clinical samples of coagulation factors (FVIII, FIX, FXI, FXII) and data from three Gene Expression Omnibus (GEO) files. She found that increased FVIII (>150%) and decreased FXII (<50%) were most common in cirrhosis (n=8), pneumonia (n=5) and sepsis (n=4). Screening of multiple datasets identified 70 shared differentially expressed genes, with protein-protein network analysis identifying CD163 as the major hub gene (rank=13). The FVIII/FXII ratio showed excellent diagnostic performance for sepsis with AUC=0.920 in ROC analysis, better than FVIII alone (AUC=0.710) or FXII (AUC=0.840). CD163 and the FVIII/FXII ratio were identified as novel biomarkers for the early detection of sepsis. Sepsis is a systemic inflammatory syndrome caused by infection with a higher mortality rate in the ICU, where early identification improves outcomes.